← Back to Search

PET Imaging for SARS-CoV-2 Sequelae

Q: Is eligibility for this medical trial open to me?

This research project is in search of 60 participants aged 18-65 who have experienced post SARS-CoV-2 sequelae. The applicant must possess high or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971, be a previous victim of the virus and suffer from neurological symptoms that have lasted at least 4 weeks prior to enrollment. Healthy control volunteers between the ages specified are also acceptable as long as they show no signs of any neurological ailments.

Q: Are people of advanced age being considered for inclusion in the experiment?

This trial's enrollment requirements state that participants must be aged 18 at the minimum and 65 or younger.

Q: Are there current opportunities to join this research experiment?

This medical research project is not actively recruiting participants, as indicated by clinicaltrials.gov which originally listed this trial on June 1st 2023 and made its last edits on December 16th 2022. Despite that, there are presently 783 other trials currently accepting new patients into their studies.

Phase < 1

Recruiting

Led By Jonathan McConathy, MD, PhD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up injection/scan date to clinical follow-up. (usually within 6 weeks)

Awards & highlights

Study Summary

This trial will use a molecule to measure inflammation in the brains of people with post-viral symptoms, compared to healthy people.

Who is the study for?

This trial is for adults aged 18-65 who have had neurological symptoms for at least four weeks after recovering from COVID-19, or healthy individuals without neurological issues. Participants must not be pregnant, lactating, severely ill, have blood disorders, autoimmune diseases (except MS), recent substance abuse, other clinical trials involvement or certain abnormal blood test results.Check my eligibility

What is being tested?

The study tests a PET/MRI imaging technique using DPA-714 to detect neuroinflammation in post-COVID patients compared with healthy subjects. It aims to visualize and measure brain inflammation linked to long-term effects of SARS-CoV-2 infection.See study design

What are the potential side effects?

As this is an imaging study involving a PET/MRI scan with the tracer DPA-714, potential side effects may include discomfort from lying still during the procedure and allergic reactions to the tracer. The MRI portion has no radiation exposure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ injection/scan date to clinical follow-up. (usually within 6 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~injection/scan date to clinical follow-up. (usually within 6 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and injection/scan date to clinical follow-up. (usually within 6 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Measurement of regional brain TSPO levels using PET in participants with neurological PASC and healthy volunteers

Trial Design

2Treatment groups

Experimental Treatment

Group I: PASCExperimental Treatment1 Intervention

Patients meeting the case definition criteria for PASC

Group II: Healty VolunteersExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,281,602 Total Patients Enrolled

Jonathan McConathy, MD, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham

5 Previous Clinical Trials

114 Total Patients Enrolled

Media Library

Healty Volunteers Clinical Trial Eligibility Overview. Trial Name: NCT05656105 — Phase < 1

SARS-CoV-2 Sequelae Research Study Groups: Healty Volunteers, PASC

SARS-CoV-2 Sequelae Clinical Trial 2023: Healty Volunteers Highlights & Side Effects. Trial Name: NCT05656105 — Phase < 1

Healty Volunteers 2023 Treatment Timeline for Medical Study. Trial Name: NCT05656105 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is eligibility for this medical trial open to me?

"This research project is in search of 60 participants aged 18-65 who have experienced post SARS-CoV-2 sequelae. The applicant must possess high or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971, be a previous victim of the virus and suffer from neurological symptoms that have lasted at least 4 weeks prior to enrollment. Healthy control volunteers between the ages specified are also acceptable as long as they show no signs of any neurological ailments."

Answered by AI

Are people of advanced age being considered for inclusion in the experiment?

"This trial's enrollment requirements state that participants must be aged 18 at the minimum and 65 or younger."

Answered by AI

Are there current opportunities to join this research experiment?

"This medical research project is not actively recruiting participants, as indicated by clinicaltrials.gov which originally listed this trial on June 1st 2023 and made its last edits on December 16th 2022. Despite that, there are presently 783 other trials currently accepting new patients into their studies."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

Jonathan E McConathy 2023. "Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05656105.

All > Coronavirus